Pharmaceuticals, Biotechnology and Life Sciences
Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for…
Catalent has completed a $30 million (€27 million) project at its facility in Limoges, France, to transform the site into a European center of excellence for biopharmaceutical development, drug product fill/finish services, and packaging.
ReNeuron Group plc (AIM: RENE), a UK-based Stem Cell and Exosomes zechnologies company, announces that Dr Tim Corn and Mark Evans have resigned as Non-Executive Directors of the Company and that Martin Walton has been appointed as a Non-Executive Director, all with immediate effect.
Leica Microsystems has introduced the new Coral Cryo workflow solution. The workflow solution enables researchers to increase their success rate…
Bristol Myers Squibb has announced that data from its cardiovascular portfolio will be presented at the American College of Cardiology’s 71st Annual Scientific Session, taking place in Washington, DC, and virtually, from April 2-4, 2022.
Moderna has submitted a request to the U.S. Food and Drug Administration (FDA) for an amendment to the emergency use authorization (EUA) to allow for a fourth dose of its COVID-19 vaccine (mRNA-1273) in adults 18 years of age and older who have received an initial booster of any of the authorized or approved COVID-19 vaccines.
Sobi has announced that the National Medical Products Administration of China (NMPA) has approved Gamifant (emapalumab) for use in China. The indication is for treatment of adult and paediatric (newborn and older) patients with primary haemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance to conventional HLH therapy.
Ginkgo Bioworks has announced the entry into a definitive agreement to acquire FGen AG (“FGen”), a Swiss company specializing in strain development and optimization.
Ignis Therapeutics and STADA’s Britannia Pharmaceuticals Ltd. affiliate have jointly announced that two companies have signed an exclusive licensing agreement under which Ignis Therapeutics will develop and commercialize subcutaneous apomorphine for Parkinson’s disease in mainland China, Hong Kong and Macau.
Kizoo portfolio company Revel Pharmaceuticals has raised $8.4M in Seed financing. The oversubscribed round was led by Kizoo Technology Capital and Starbloom Capital with participation from Tubus LLC. The funds will support Revel as it advances its repair-based enzyme therapy pipeline towards the clinic.